Anne Wojcicki, the CEO of 23andMe, is navigating a challenging phase as the company faces the resignation of all seven board members amid strategic disagreements. The company, known for its mail-order DNA testing kits, has struggled to achieve profitability since its merger with a special purpose acquisition company ( SPAC ) in 2021. This financial instability has resulted in a plummeting stock value, which hit a low of $0.30 before rebounding slightly to $0.36. The board members included representatives from Sequoia Capital, with Roelof Botha and Neal Mohan among them.